Tag: aurobindo-pharma-arm-acquires-non-oncology-portfolio-of-khandelwal-labs

Aurobindo Pharma subsidiary Auro Pharma is acquiring the non-oncology prescription formulations business of Khandelwal Laboratories in a slump sale for a cash consideration of ₹325 crore, subject to working capital true-up adjustments under the definitive agreements, Aurobindo said in a filing on Thursday.

The business comprises 23 brands marketed across 67 SKUs and nine pipeline products, with anti-infective and pain management as its major portfolios.

It reported turnover of ₹113.5 crore in 2024-25 and an EBITDA of ₹28.9 crore. The operation includes a field force of about 470 people and more than 1,600 stockists and related distribution infrastructure.

The transaction, effective January 1, 2026, will add brands in pain management and anti-infective, complement Aurobindo’s existing product portfolio and support expansion in the domestic market.

Auro Pharma, a subsidiary of Aurobindo Pharma, will acquire the non-oncology prescription formulations business of Khandelwal Laboratories on a going-concern, slump-sale basis for a cash consideration of ₹325 crore, subject to working capital true-up as per the definitive agreements, Aurobindo Pharma said in a filing on Thursday.

The acquired business comprises 23 brands marketed across 67 SKUs and nine pipeline products, with anti-infective and pain management as its major portfolios. It reported turnover of ₹113.5 crore in 2024-25 and an EBITDA of ₹28.9 crore.

The business includes a field force of about 470 and more than 1,600 stockists and distribution-related infrastructure. The acquisition, effective January 1, 2026, is expected to add brands in pain management and anti-infective, complement Auro Pharma’s existing product portfolios and support expansion in the domestic market.

Aurobindo Pharma’s subsidiary Auro Pharma is acquiring the non-oncology prescription formulations business of Khandelwal Laboratories on a going concern, slump-sale basis for a cash consideration of ₹325 crore, subject to working capital true-up adjustments as provided in the definitive agreements, Aurobindo Pharma said in a filing on Thursday.

The acquired business comprises 23 brands marketed in 67 SKUs and nine pipeline products, with anti-infective and pain management as its major portfolios.

The business generated a turnover of ₹113.5 crore in 2024-25 and reported an EBITDA of ₹28.9 crore. It supports a field force of about 470 personnel and more than 1,600 stockists and other distribution assets.

The acquisition, effective January 1, 2026, is expected to add brands in pain management and anti-infectives, complement Auro Pharma’s existing product portfolios and help expand its domestic market presence.